Updated Jul 16, 2026
Cheng Andrew has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $13.35M.
Andrew Cheng is the President and CEO of Akero Therapeutics, Inc., a biotechnology company focused on developing treatments for liver diseases. He has been involved in various roles within the biotech industry, contributing to advancements in therapeutic development.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 159.8K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 277.1K | — | |
| 2025-11-21 | AKRO | Akero Therapeutics, Inc. | G — Bona-fide gift | 74.5K | $0.00 | |
| 2025-11-14 | AKRO | Akero Therapeutics, Inc. | G — Bona-fide gift | 14.7K | $0.00 | |
| 2025-10-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 30.0K | $53.98 | $1.62M |
| 2025-10-10 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 30.0K | $19.87 | $596K |
| 2025-10-08 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 52.2K | $0.61 | $32K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 1.8K | $43.02 | $77K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 158 | $44.62 | $7K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 7.3K | $43.99 | $322K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 22.5K | $42.99 | $968K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 1.9K | $19.87 | $38K |
| 2025-09-10 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 13.0K | $6.36 | $83K |
| 2025-08-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 400 | $49.44 | $20K |
| 2025-08-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 18.8K | $48.87 | $919K |
| 2025-08-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 10.8K | $48.07 | $519K |
| 2025-07-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 15.3K | $51.73 | $792K |
| 2025-07-10 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 14.7K | $50.57 | $743K |
| 2025-06-30 | AKRO | Akero Therapeutics, Inc. | A — Grant or award | 890 | $23.87 | $21K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | A — Grant or award | 98.5K | $0.00 |
Andrew Cheng is the President and CEO of Akero Therapeutics, Inc., a biotechnology company focused on developing treatments for liver diseases. He has been involved in various roles within the biotech industry, contributing to advancements in therapeutic development.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 18 open-market sales ($13.35M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Cheng Andrew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.